In Minnesota, health-related cannabis was authorized for use in 2014. From July 2015 to February 2019, our center certified 103 pediatric and young adult individuals for the use of health-related cannabis under the qualifying situations of cancer and therapy-connected symptoms. Right here, we supply a evaluation of the literature on health-related cannabis use in pediatric and young adult cancer individuals. We also supply demographic information on our individuals certified for health-related cannabis. The most frequent diagnoses have been leukemia/lymphoma (36%), brain tumors (37%), and malignant strong tumors (26%). The most frequent indications have been chemotherapy-connected nausea, discomfort, and cancer cachexia. The age variety at certification was 1.four-28.7 years (median 15.three years). The time from cancer diagnosis to certification ranged from .five-197 months (median eight.9 months). The majority (94%) have been certified throughout their very first line of therapy. In the 32 individuals who died from recurrent or progressive cancer, the time from certification to death was 1.three-30.three months (median four.four years). Regardless of requesting certification, a subset (24%) in no way had health-related cannabis dispensed. In our knowledge, pediatric and young adult oncology individuals are interested in health-related cannabis to assist handle therapy-connected symptoms. Ongoing evaluation of this information will determine the therapeutic efficacy of health-related cannabis.
Copyright © 2018 Elsevier B.V. All rights reserved.
PMID: 31212902 PMCID: PMC6617193 DOI: 10.3390/young children6060079
Skrypek MM1, Bostrom BCtwo, Bendel AEthree.